William Rusche, MD
Rheumatology · Bloomington, INNPI 1134202880
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,845 of the $10,194 with a category attached, or 77.0%. 39 manufacturers reported payments, led by Pfizer at 32.2% of the total. Reporting peaked in 2022 at $2,894 and has fallen 50.3% since, to $1,438 in 2025.
Across 621 payments — averaging $16.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- AbbVie$2K
- Amgen$2K
- Johnson & Johnson$908
- Novartis$395
- UCB, Inc.$234
- plus $2K from 33 others
What the payments were for
- Consulting fees$1,85018%
- Food & beverage$7,84577%
- Education$5005%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 158 | $3,279 |
| AbbVie | 177 | $1,892 |
| Amgen(2 entities) | 114 | $1,590 |
| Johnson & Johnson | 40 | $908 |
| Novartis | 21 | $395 |
| UCB, Inc. | 11 | $234 |
| AstraZeneca(2 entities) | 10 | $191 |
| E.r. Squibb & Sons, L.L.C. | 11 | $189 |
| Mallinckrodt Hospital Products Inc. | 7 | $183 |
| Lilly USA, LLC | 8 | $152 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Sanofi | 6 | $104 |
| ANI Pharmaceuticals, Inc. | 4 | $104 |
| Novo Nordisk | 5 | $95 |
| Bristol Myers Squibb | 5 | $86 |
| Boehringer Ingelheim | 4 | $85 |
| Genentech USA, Inc. | 3 | $50 |
| Sobi, Inc | 3 | $48 |
| GSK | 3 | $47 |
| Organon | 2 | $45 |
| Exact Sciences | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $38 |
| Medline Industries LP | 2 | $37 |
| Scilex Pharmaceuticals Inc. | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $24 |
| Bioventus LLC | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 3 | $23 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Vertex | 1 | $20 |
| La Jolla Pharmaceutical Company | 1 | $17 |
| Aroa Biosurgery Incorporated | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Innocoll Pharmaceuticals Limited | 1 | $13 |
| Convatec Inc. | 1 | $12 |
| Collegium Pharmaceutical, Inc. | 1 | $12 |
| Mayne Pharma Commercial LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XELJANZ$1,850
How this compares
$10,194 in reported general payments places this provider in the 80th percentile of 106 rheumatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 105 | $859,776 |
| Orencia ClickjectAbatacept | 79 | $599,044 |
| Enbrel SureclickEtanercept | 61 | $454,445 |
| Skyrizi PenRisankizumab-Rzaa | 15 | $308,922 |
| Enbrel MiniEtanercept | 42 | $304,377 |
| EnbrelEtanercept | 23 | $256,319 |
| HumiraAdalimumab | 15 | $230,608 |
| Xeljanz XrTofacitinib Citrate | 31 | $212,655 |
| Taltz AutoinjectorIxekizumab | 27 | $182,488 |
| OtezlaApremilast | 37 | $176,555 |
| Humira PenAdalimumab | 16 | $158,150 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 18 | $130,796 |
| RinvoqUpadacitinib | 14 | $101,883 |
| ActemraTocilizumab | 28 | $96,559 |
| KevzaraSarilumab | 17 | $72,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Otezla | $1,590 | $432,87460 claims |
| AbbVieHumira, Rinvoq, Savella | $1,892 | $343,64641 claims |
| SanofiKevzara | $104 | $72,23317 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er | $12 | $6,31711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 106 rheumatology providers in Indiana.
Other rheumatology in Bloomington
- David BattIndianapolis$577K
- Kathleen ThomasNoblesville$511K
- Keith ReichDyer$193K
- Douglas SmithIndianapolis$147K
- Ahmad SalahMerrillville$139K
- Inna AroutiounovaIndianapolis$102K
- James CohenIndianapolis$76K
- Nina RamessarFort Wayne$75K
- Anita ZachariahMunster$37K
- James EhlichIndianapolis$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.